DUPARC
Dutch Parkinson Cohort...
Description
The DUPARC study is a single center, prospective, observational study of newly diagnosed patients with Parkinson's disease with follow-up after one year and three years, with the intention of an extended follow-up with three-year intervals. The DUPAR...
General Design
- Cohort type
Clinical cohort
- Design
Longitudinal
- Design description
DUPARC is a prospective cohort study in which 150 de novo PD subjects are included. Participants receive follow-up assessments after 1 year and 3 years, with the intention of an extended follow-up with 3 year intervals. Subjects are extensively characterized to primarily assess objectives within three major domains of PD: cognition, gastrointestinal function and vision.
- Design schematic
- Design schematic
- Start/End year
2017 - ongoing
- Countries
Netherlands (the)
- Regions
Drenthe, Friesland, Groningen
- Number of participants
150
- Number of participants with samples
150
- Age group at inclusion
Adult (18+ years)
- Main medical condition
- VI Diseases of the nervous system
- G20-G26 Extrapyramidal and movement disorders
- G20 Parkinson disease
- Marker paper
- Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology
- PID
https://doi.org/10.34760/6526633dab6fe
Contact and Contributors
- prof. dr. T (Teus) van Laart.van.laar@umcg.nl
- dr. S (Sygrid) van der Zees.van.der.zee01@umcg.nl
Available Data & Samples
Data categories
- Biological samples
- Imaging data
- Other
Sample categories
- Fluids and Secretions
- Blood
- Blood (whole)
- Serum
- Plasma
- Saliva
- Feces
Areas of information
- Socio-demographic and economic characteristics
- Age/birthdate
- Sex/gender
- Education
- Language
- Lifestyle and behaviours
- Tobacco
- Alcohol
- Drugs
- Nutrition
- Sleep
- Perception of health, quality of life, development and functional limitations
- Quality of life
- Functional limitations
- Other perception of health, quality of life and functional limitation-related information
- Medication and supplements
- Medication and supplement intake
- Other and unspecified pharmacological interventions
- Physical measures and assessments
- Physical characteristics
- Muscles, skeleton and mobility
- Brain and nerves
- Speech and voice
- Other physical measures and assessments
- Laboratory measures
- Other laboratory measures
- Cognition, personality and psychological measures and assessments
- Cognitive functioning
- Psychological distress and emotions
- Other psychological measures and assessments
- Administrative information
- Physical and cognitive measure and biosample-related information
Subpopulations
List of subcohorts or subpopulations for this resource...
| Name | Description | Number of participants |
|---|
Collection events
List of collection events defined for this resource...
| Name | Description | Participants | Start end year |
|---|
Partners
Funding & Citation requirements
- Funding
The DUPARC study is funded by two grants from the W. Garfield Weston Foundations’ Weston Brain Institute. JMB has received personal grants to cover personnel costs. AC has received funding for personnel costs by the European Union Horizon 2020 grant No 661883, European Glaucoma Research Training Program (EGRET). No funding agency was involved in the design of the study; the collection, analysis and interpretation of data; or in writing the manuscript.
- Citation requirements
We thank all patients, caregivers, health care professionals, students and institutions who have contributed and collaborated in this project. In particular, we would like to thank Renée Speijers, Yvonne Nijman and Hanna Slomp for their help in the recruitment and logistics of the study. The Parkinson Platform Northern Netherlands (PPNN) Study Group collaborators. Verwey NA1, Van Harten B1, Portman AT2, Langedijk MJH2, Oomes PG2, Jansen BJAM2, Van Wieren T2, Van den Bogaard SJA3, Van Steenbergen W3, Duyff R3, Van Amerongen JP3, Fransen PSS4, Polman SKL4, Zwartbol RT4, Van Kesteren ME4, Braakhekke JP4, Trip J4, Koops L4, De Langen CJ4, De Jong G4, Hartono JES4, Ybema H4, Bartels AL5, Reesink FE5, Postma AG6, Vonk GJH7, Oen JMTH7, Brinkman MJ7, Mondria T7, Holscher RS7, Van der Meulen AAE8, Rutgers AWF8, Boekestein WA9, Teune LK9, Orsel PJL10, Hoogendijk JE10, Van Laar T11. 1Department of Neurology, Medisch Centrum Leeuwarden, Leeuwarden, the Netherlands; 2Department of Neurology, Treant Zorggroep locations, Stadskanaal, Emmen, Hoogeveen, the Netherlands; 3Department of Neurology, Tjongerschans Ziekenhuis Heerenveen, Heerenveen, the Netherlands; 4Department of Neurology, Isala, Zwolle, Meppel, the Netherlands; 5Department of Neurology, Ommlander Ziekenhuis Groningen, Scheemda, the Netherlands; 6Department of Neurology, Nij Smellinghe Ziekenhuis Drachten, Drachten, the Netherlands; 7Department of Neurology, Antonius Zorggroep, Sneek, the Netherlands; 8Department of Neurology, Martini Ziekenhuis, Groningen, the Netherlands; 9Department of Neurology, Wilhelmina Ziekenhuis Assen, Assen, the Netherlands; 10Department of Neurology, Sionsberg, Dokkum, the Netherlands; 11Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands.